Abstract
Antibodies against native glycosylated myelin-oligodendrocyte-glycoprotein (MOG) were measured by ELISA in patients with multiple sclerosis (MS) and controls. Anti-MOG IgM antibodies were elevated during the first demyelinating event. Higher MOG-specific IgG antibodies were found in patients during relapses and in secondary chronic progressive MS compared to patients in remission and healthy controls. Antibodies against native MOG may be a potential biomarker for MS.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
Aged
-
Animals
-
Antibody Specificity
-
Autoantibodies / blood
-
Autoantibodies / immunology*
-
Demyelinating Diseases
-
Female
-
Glycosylation
-
Humans
-
Immunoglobulin G / blood
-
Immunoglobulin G / immunology*
-
Immunoglobulin M / blood
-
Immunoglobulin M / immunology*
-
Male
-
Mice
-
Middle Aged
-
Multiple Sclerosis, Chronic Progressive / immunology*
-
Multiple Sclerosis, Relapsing-Remitting / immunology*
-
Myelin Proteins
-
Myelin-Associated Glycoprotein / chemistry
-
Myelin-Associated Glycoprotein / immunology*
-
Myelin-Associated Glycoprotein / isolation & purification
-
Myelin-Oligodendrocyte Glycoprotein
-
Protein Processing, Post-Translational*
Substances
-
Autoantibodies
-
Immunoglobulin G
-
Immunoglobulin M
-
MOG protein, human
-
Mog protein, mouse
-
Myelin Proteins
-
Myelin-Associated Glycoprotein
-
Myelin-Oligodendrocyte Glycoprotein